HER2向结构的结构基础活动由DARPin G3和白蛋白结合域组成
Anastasia G Konshina1, Eduard V Bocharov1,2, Elena V Konovalova1,3
1Shemyakin & Ovchinnikov KT, Russian Academy of Sciences, Moscow 117997, Russia.
International journal of molecular sciences
|November 9, 2024
概括
与白蛋白结合域 (ABD) 融合的非免疫球蛋白支架蛋白 (SP) 显示出向HER2的潜力. 它们的结合效率取决于SP G3和ABD的顺序,受域间接触和链接器长度的影响.
科学领域:
- 生物化学 生物化学
- 结构生物学 结构生物学
- 蛋白质工程是指蛋白质工程.
背景情况:
- 非免疫球蛋白支架蛋白 (SPs) 是治疗点的关键高亲和度结合剂,包括癌症相关的受体氨酸激酶.
- HER2是一种受体氨酸激酶,是基于SP的疗法的重要标.
- 与血清白蛋白的融合延长了SPs的循环时间,并减少了脏积累.
研究的目的:
- 调查ABD-G3和G3-ABD结构的差异性HER2结合活性背后的结构和动态机制.
- 了解支架蛋白 (SP) G3和白蛋白结合域 (ABD) 的顺序如何影响结合和稳定性.
- 为设计改进的基于SP的治疗方法提供结构性基础.
主要方法:
- 利用核磁共振 (NMR) 光谱学来分析嵌合蛋白的结构和动态特性.
- 采用分子建模技术来补充生物物理数据.
- 评估了不同结构安排中的域间联系,绑定接口和复杂稳定性.
主要成果:
- 在ABD-G3和G3-ABD结构中观察到广泛的域间接触,结合接口和稳定性的变化.
- 域链接器显著影响蛋白质-蛋白质结合部位的可访问性,这取决于序列顺序.
- G3模块的位置极大地影响HER2结合活性.
结论:
- 支架蛋白 (SP) G3和白蛋白结合域 (ABD) 的排列影响了融合蛋白的整体结构,动态和结合能力.
- 了解这些结构-功能关系对于合理设计针对信号受体的基于SP的新型治疗方法至关重要.
- 这项研究为开发利用工程蛋白质开发更有效的癌症疗法提供了基础的见解.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K


